PRESS RELEASE
12 November 2026

PlaqueTec's BIOPATTERN trial passes 100 patients and expands to 8 NHS centres

- *100th patient recruited into 300-patient trial mapping patient-specific disease mechanisms at the site of coronary plaque*
- *Four additional NHS cardiac centres join: St Bartholomew's Hospital, London, Leeds General Infirmary, Blackpool Victoria and Queen Elizabeth Birmingham*
- *Trial data feed PlaqueTec's BioCarta repository, supporting the discovery of novel drug targets for precision medicines and new diagnostic approaches*

Cambridge, UK, 12 November 2026: PlaqueTec, a medtech company pioneering intracoronary liquid biopsy to reveal the biological drivers of atherosclerotic cardiovascular disease (ASCVD), today announced that its BIOPATTERN clinical trial has recruited its 100th patient and expanded to eight NHS specialist cardiac centres. St Bartholomew's Hospital, London, and Leeds General Infirmary are now recruiting, with Blackpool Victoria and Queen Elizabeth Birmingham set up and ready to start. BIOPATTERN aims to uncover the patient-specific mechanisms driving coronary artery disease (CAD) and identify novel drug targets for personalised medicines. Recruitment towards the 300-patient target is expected to complete in 2027.

CAD is the most common form of ASCVD, the world's leading cause of death. Yet treatment remains largely one-size-fits-all, leaving many patients at risk of a heart attack. BIOPATTERN uses PlaqueTec's Liquid Biopsy System™ (LBS) to sample blood directly at the site of coronary plaque. Measuring thousands of biomolecules where the disease is happening gives a more accurate, disease-specific picture than systemic samples can provide. These data feed BioCarta, PlaqueTec's growing repository of unique intracoronary proteomic and clinical data, which will help define and diagnose patient sub-groups and new therapeutic targets to guide patient stratification and drug development.

The additional centres join Royal Papworth Hospital, Cambridge; Norfolk and Norwich University Hospital; Royal Bournemouth Hospital; and the Bristol Heart Institute, extending BIOPATTERN's network across England. The trial is run by Papworth Trials Unit Collaboration with PlaqueTec and overseen by a Trial Steering Committee chaired by Professor Peter Libby (Mallinckrodt Professor of Medicine, Harvard Medical School, and President of the International Atherosclerosis Society).

Dr Stephen Hoole, Consultant Cardiologist, Royal Papworth Hospital, and BIOPATTERN trial Chief Investigator, commented: *"One-size-fits-all treatment for coronary disease leaves many patients carrying significant residual risk. PlaqueTec's site-of-disease approach aims to reveal the mechanisms underlying disease in individual patients, and holds real potential to drive a new generation of precision medicines for atherosclerotic disease."*

Dr Simon Williams, General Manager, PlaqueTec, said: *"BIOPATTERN aims to close the knowledge gap in CAD and pave the way for precision therapies where unmet need remains high. Passing 100 participants and growing to eight NHS centres is important progress. We're grateful to our NHS clinical partners and to every patient taking part."*

To learn more about the BIOPATTERN trial, please visit https://www.plaquetec.com/our-research.

ENDS

Notes to Editors:



Dr Stephen Hoole, Consultant Cardiologist, Royal Papworth Hospital



Dr Simon Williams, General Manager, PlaqueTec

For high-resolution images, please contact Zyme Communications.

Media contact
Anna Bakewell
Zyme Communications
Tel: +44(0) 7801 098 242
Email: anna.bakewell@zymecommunications.com

To opt out from receiving press releases from Zyme Communications please email info@zymecommunications.com. To view our privacy policy please click here.

About PlaqueTec www.plaquetec.com
PlaqueTec is advancing precision medicine in atherosclerotic cardiovascular disease by using site-of-disease biology to improve understanding of patient-specific mechanisms and support targeted therapeutic development.

Atherosclerotic disease causes plaque build-up that narrows or blocks the arteries that supply blood to the heart, brain and limbs, and is a leading cause of death globally. Current treatment approaches are largely one-size-fits-all and therefore ineffective for many patients. To address this, PlaqueTec has developed a proprietary technology and data analysis platform to endotype patients and uncover potential biomarkers of coronary vascular function and plaque progression.

A more detailed understanding of patient endotypes will support drug development by identifying new targets in specific patient groups, reducing clinical trial sizes and costs, and increasing success rates, ultimately improving outcomes for patients.

The Company is based at the world-renowned Babraham Research Campus, Cambridge, UK.

Follow PlaqueTec on LinkedIn @PlaqueTec Ltd. and X @PlaqueTec_UK.